24/7 Wall Street
17 Sept 2026, 15:47 UTC · 1h ago
Verdict
Headline leans bullish. We score TEM +0.90 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish · 1 new · 4 priced in
Morgan Stanley highlighted that clarified reimbursement pricing for xT and xF diagnostics could add $330 million to $400 million in combined annual revenue.
Newremarks on September 15
So whatThis incremental lift represents roughly a 20-25% increase over the current FY2026 revenue guidance of ~$1.6 billion.
More positive than 98% of claims this week
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Tempus AI reported $200 million in data licensing bookings for Q2 from clients including AstraZeneca, GSK, and Merck.
Priced inprepared remarks from the Q2 call
So whatHigh-margin licensing bookings accelerate the path to positive free cash flow targeted by year end.
More positive than 91% of claims this week
Forward EPS estimates for fiscal 2027 have shifted from -$0.1067 ninety days ago to $0.0040 today.
Priced intrend over the past ninety days
So whatThe swing to a positive estimate suggests the market expects a break-even inflection point by FY2027.
More positive than 84% of claims this week
The company raised its full-year revenue guidance to between $1.595 billion and $1.605 billion.
Priced inreported in Q2 results
So whatThis guidance represents a ~25% growth rate, which serves as the baseline for the CEO's claim that they will 'over-deliver'.
More positive than 77% of claims this week
Tempus AI recorded $54.1 million in stock-based compensation in Q2.
Priced inreported in Q2 results
So whatHeavy SBC creates ongoing dilution for shareholders despite the operational revenue growth.
More negative than 73% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Shares surged 30% following Morgan Stanley's positive revenue outlook and increased reimbursement clarity.
More positive than 51% of ticker scores this week
Named as a customer contributing to Tempus AI's strong data licensing bookings.
More positive than 51% of ticker scores this week
Named as a customer contributing to Tempus AI's strong data licensing bookings.
More positive than 51% of ticker scores this week
Named as a customer contributing to Tempus AI's strong data licensing bookings.
More positive than 51% of ticker scores this week
Named as a customer contributing to Tempus AI's strong data licensing bookings.
More positive than 45% of ticker scores this week
Mentioned as the analyst firm driving positive sentiment and revenue reframing for Tempus AI.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
More positive than 57% of relationship scores this week
[a_to_b] Bristol-Myers Squibb is a named customer for Tempus AI's data licensing bookings.
More positive than 57% of relationship scores this week
[a_to_b] GSK is a named customer for Tempus AI's data licensing bookings.
More positive than 57% of relationship scores this week
[a_to_b] Merck is a named customer for Tempus AI's data licensing bookings.
+14.0%
Price agrees with the score
$79.74 vs $69.97 close before publication (Sep 16) · not market-adjusted
TEM chart →
